REGENXBIO Inc.
Public company- Headquarters
- ROCKVILLE, Maryland
- Industry
- Biotechnology
- Ticker
- RGNX
- CIK
- 0001590877
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| DirectorKenneth T. Mills | Oct 16, 2026 | Departed |
| Chairman of the BoardGeorge Migausky | Oct 16, 2026 | Appointed |
| Class II director of the CompanyGregory Ciongoli | Aug 25, 2026 | Appointed |
| director of the CompanyJean Bennett, M.D., Ph.D. | Aug 25, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- ANAVEX LIFE SCIENCES CORP.
CEO appointed: Terrie Kellmeyer, Ph.D.
- RECURSION PHARMACEUTICALS, INC.
Chair of the Board appointed: Fred Hassan
- Vir Biotechnology, Inc.
Class III director appointed: Suzanne Topalian, M.D.
- AMGEN INC
director appointed: David W. Gibbs
- Executive departure
Director departs: Kenneth T. Mills
Kenneth T. Mills, Director of REGENXBIO Inc., resigns the role, effective October 21, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: Director
- Executive appointment
Chairman of the Board appointed: George Migausky
George Migausky was named Chairman of the Board of REGENXBIO Inc.. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 16, 2026Role: Chairman of the Board
- Executive appointment
Class II director of the Company appointed: Gregory Ciongoli
Gregory Ciongoli was named Class II director of the Company of REGENXBIO Inc., effective August 25, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 25, 2026Role: Class II director of the Company
- Executive departure
director of the Company departs: Jean Bennett, M.D., Ph.D.
Jean Bennett, M.D., Ph.D., director of the Company of REGENXBIO Inc., resigns the role, effective August 25, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 25, 2026Role: director of the Company
- Executive departure
director of the Company departs: A.N. “Jerry” Karabelas, Ph.D.
A.N. “Jerry” Karabelas, Ph.D., director of the Company of REGENXBIO Inc., resigns the role, effective August 25, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 25, 2026Role: director of the Company
Last verified Nov 8, 2026